JASCAYD^{® (Nerandomilast) Approved in China for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)}

Boehringer Ingelheim’s JASCAYD^® has been approved by China’s National Medical Products Administration as an oral treatment option for idiopathic pulmonary fibrosis in adult patients.